A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis

Trial Profile

A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Tuberculosis vaccine (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Sponsors Aeras
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 May 2015 Treatment lines amended; dosage in the groups were revised.
    • 17 Apr 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top